Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The objective of the study is to compare the safety and efficacy of masitinib at 4.5 mg/kg/day or masitinib at 4.5 mg/kg/day with a dose escalation to 6 mg/kg/day after three month of treatment versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis. Primary endpoint: Multiple Sclerosis Functional Composite (MSFC) at week 96
Inclusion criteria
- Primary progressive or relapse-free secondary progressive multiple sclerosis